GLP-1 and Muscle Loss: Causes, Risk Factors, Protein Requirements, and Evidence-Based Prevention Strategies
Here's the uncomfortable truth about GLP-1 drugs that doesn't always make the headlines alongside the remarkable weight loss results: some of that weight being lost is muscle, not fat. In clinical trial data, lean body mass (which includes muscle) can account for 25–40% of total weight lost on semaglutide or tirzepatide. For a person who loses 30 pounds on Ozempic, that could mean 8–12 pounds of that loss came from muscle tissue. That's a serious problem — not just aesthetically, but metabolically and functionally. The good news is that this is not inevitable. With the right strategy, you can preserve — and even build — muscle while losing substantial fat on GLP-1 therapy. But it requires deliberate, evidence-based action, not passive hope.
The Problem: How Much Muscle Are We Actually Talking About?
Let's start with the data, because the numbers are more sobering than most patients are told.
STEP 1 Trial (Semaglutide): The DEXA Substudy
The STEP 1 trial tested semaglutide 2.4 mg/week for 68 weeks, producing a mean weight loss of about 15%. In the DEXA (dual-energy X-ray absorptiometry) body composition substudy, participants lost:
- Fat mass: ~10.4 kg (approximately 25% reduction)
- Lean soft tissue (LST): ~6.9 kg (approximately 13% reduction)
The LST loss accounted for roughly 40% of total weight lost. In other words, for every 10 pounds lost, about 4 pounds were lean tissue.
SURMOUNT-1 Trial (Tirzepatide): DEXA Substudy
Tirzepatide at 5–15 mg/week over 72 weeks produced up to 21% mean weight loss. The DEXA substudy found:
- Fat mass reduction: ~15.9 kg (approximately 34% reduction)
- Lean soft tissue reduction: ~5.6 kg (approximately 11% reduction)
LST loss accounted for approximately 26% of total weight lost — somewhat better than semaglutide, with fat comprising approximately 74–75% of total weight loss across doses.
A recent network meta-analysis confirmed that approximately 25% of weight loss during GLP-1 and GLP-1/GIP RA therapy is attributed to lean loss — an average across multiple compounds. The Endocrine Society's 2025 ENDO meeting data reinforced this: approximately 40% of weight lost from semaglutide comes from lean mass when protein intake is inadequate.
Critically, these baseline trial figures are from participants receiving only general lifestyle counseling — not structured resistance training or optimized protein protocols. This matters enormously, because studies with structured resistance training show dramatically different outcomes.
Why Does This Happen? The Biology of Caloric Restriction-Induced Catabolism
GLP-1 drugs do not directly destroy muscle. There is no known direct catabolic effect of semaglutide or tirzepatide on muscle tissue. The muscle loss happens because of what the drugs do: they dramatically suppress appetite and caloric intake. This creates a state of prolonged caloric deficit — and in a caloric deficit without adequate countermeasures, the body is forced to break down muscle protein for energy.
The Molecular Mechanism: mTOR, Insulin, and Nitrogen Balance
mTORC1 (mechanistic Target of Rapamycin Complex 1) is the master regulator of muscle protein synthesis. When you eat adequate protein and engage in resistance exercise, mTORC1 signals muscles to build new protein. When you eat too little — particularly too little protein — mTORC1 activity falls, and the body enters a state of negative nitrogen balance: protein breakdown exceeds protein synthesis.
Insulin's role: Insulin is anabolic for muscle. It promotes amino acid uptake into muscle cells and suppresses the breakdown of muscle protein. GLP-1 drugs improve insulin sensitivity overall, which should theoretically be protective for muscle. However, if caloric intake is very low and insulin levels drop substantially (as they do in extended fasting-like states), the anabolic signal weakens.
Cortisol and glucagon elevation: Prolonged caloric restriction increases cortisol (a catabolic hormone that promotes muscle breakdown) and may alter glucagon/insulin ratios in ways that shift the body toward protein catabolism.
The net result: if you are on a GLP-1 drug eating 900–1,200 calories per day without intentional protein loading and resistance training, your body is in an extended state of muscle catabolism. The fat is coming off — but so is the muscle.
Why Muscle Loss Is Dangerous Long-Term
This isn't a cosmetic concern. Muscle loss has cascading metabolic and functional consequences:
Reduced Resting Metabolic Rate (RMR)
Muscle is metabolically active tissue — it burns calories at rest. Every pound of muscle lost reduces your baseline caloric needs. This is one of the key reasons that weight regain is so common after any significant weight loss: the metabolism has slowed because lean mass was lost alongside fat. If you regain weight afterward (a very real risk when GLP-1 drugs are stopped), it typically comes back as fat, not muscle — a phenomenon called body composition rebound or "skinny fat" syndrome.
Sarcopenia Risk
Sarcopenia — pathological loss of skeletal muscle mass and function — is already a major concern for aging adults. Losing 5–7 kg of lean mass during GLP-1 therapy can meaningfully accelerate sarcopenia progression, particularly in people over 60. Sarcopenia is associated with increased falls, fractures, disability, and mortality.
Impaired Insulin Sensitivity
This is paradoxical: GLP-1 drugs improve insulin sensitivity overall, but significant muscle loss can counteract this benefit. Skeletal muscle is the primary site of insulin-stimulated glucose disposal — accounting for 70–80% of post-meal glucose uptake. Less muscle means less capacity to clear blood glucose, potentially undermining one of the core metabolic goals of GLP-1 therapy.
Functional Strength Decline
Beyond metabolism, losing 5–7 kg of functional muscle means reduced strength, reduced exercise capacity, and impaired ability to perform daily activities — particularly problematic for older adults.
Who Is at Highest Risk for Muscle Loss?
Not everyone loses the same proportion of muscle on GLP-1 therapy. Risk factors for disproportionate lean mass loss include:
- Low protein intake: The single most modifiable risk factor. Patients eating under 80g of protein/day face dramatically higher muscle loss.
- Sedentary lifestyle: No resistance training means no anabolic stimulus to counter catabolism.
- Older age: Muscle protein synthesis becomes less efficient with age (anabolic resistance), requiring higher protein intakes and more resistance exercise to achieve the same muscle-building signal. The ENDO 2025 data specifically identified older age as a risk factor for greater muscle loss on semaglutide.
- Female sex: Also identified in the ENDO 2025 semaglutide study as a risk factor for greater lean mass loss, possibly related to estrogen's role in muscle metabolism.
- Rapid dose escalation: Faster escalation produces more rapid weight loss, which is associated with higher proportional lean mass loss.
- Very low caloric intake: Eating below 1,000–1,200 kcal/day chronically creates severe negative nitrogen balance.
The Protein Imperative: Evidence and Practical Targets
If there is one intervention that is non-negotiable during GLP-1 therapy, it is adequate protein intake. The scientific consensus is clear:
The Evidence Base
A landmark meta-regression by Morton et al. (2018) established that muscle protein synthesis response to protein intake plateaus at approximately 1.6g/kg of body weight per day under conditions of resistance training. This is the threshold used in the active LEAN-PREP clinical trial (NCT06885736) specifically investigating protein and resistance training for lean mass preservation during GLP-1 therapy.
For people with higher levels of obesity, targets are typically calculated against lean body mass or ideal body weight rather than actual body weight — to avoid unrealistically high targets. In practice, most expert guidance recommends:
- Minimum baseline: 1.2g protein per kg actual body weight per day
- Optimal range for muscle preservation: 1.6–2.2g/kg ideal body weight per day
- Older adults and women (higher risk groups): Target the upper end of this range
Practical Protein Sources
| Protein Source | Protein Content | Bioavailability | Practical Notes |
|---|
| Chicken breast (4 oz) | ~35g | Very high (DIAAS ~1.0) | Lean, versatile; good first-meal protein |
| Greek yogurt (1 cup) | ~20–25g | High | High leucine; good post-workout option |
| Eggs (3 large) | ~18g | Very high | Convenient; complete amino acid profile |
| Salmon (4 oz) | ~30g | Very high | Anti-inflammatory omega-3 bonus |
| Cottage cheese (1 cup) | ~25–28g | High | High casein for slower release |
| Whey protein shake | ~25g | Very high (DIAAS ~1.25) | Fastest absorption; ideal post-exercise |
| Tofu (½ block) | ~20g | Moderate | Lower leucine per gram than animal sources |
| Lentils (1 cup cooked) | ~18g | Lower (~70%) | Must be combined with other sources |
Animal vs. plant protein: Animal proteins have higher biological value and better digestibility-corrected amino acid scores (DIAAS), meaning more of the protein you eat actually becomes available for muscle synthesis. This matters during caloric restriction, when every protein gram counts. If you are vegetarian or vegan, you need to eat more total protein (approximately 20–30% more) to achieve the same muscle synthesis stimulus.
The Leucine Threshold Concept
Not all amino acids drive muscle protein synthesis equally. Leucine is the primary trigger for mTORC1 activation — the molecular switch for muscle building. Each meal needs a minimum leucine dose (approximately 2.5–3g) to maximally stimulate muscle protein synthesis. This is why whey protein (high in leucine) is more anabolic per gram than most plant proteins. Distributing protein across 4–5 meals throughout the day, with each containing 25–40g of high-quality protein, is more effective than consuming the same total in one or two large meals.
Resistance Training: The Single Most Important Intervention
Protein without resistance training is necessary but insufficient. The anabolic stimulus from mechanical muscle loading — lifting weights — activates mTORC1 through a separate pathway (integrin signaling, satellite cell activation) that is synergistic with dietary protein. Together, they produce muscle protein synthesis rates that far exceed either alone.
What the Evidence Shows
A case series published in SAGE Open Medical Case Reports (2025) followed three patients on semaglutide or tirzepatide who performed structured resistance training 3–5 days per week:
- Patient 1: Lost 33% total body weight; 91.2% of loss was fat, only 8.7% lean tissue
- Patient 2: Lost 26.8% body weight; LST increased by 2.5% (net lean mass gained while losing significant weight)
- Patient 3: Lost 13.2% body weight; LST increased by 5.8%
Compared to the trial averages (26–40% of weight loss as lean tissue), these outcomes are dramatically better. Two of the three patients actually built muscle while losing substantial total body weight — a feat that requires consistent resistance training.
A prior study by Lundgren et al. demonstrated that adding exercise to liraglutide treatment preserved fat-free mass and potentiated fat loss compared to drug plus diet counseling alone.
Optimal Training Protocol
Frequency: 3–5 days per week of resistance training is ideal. Even 2 sessions/week show benefit over none.
Exercise selection: Prioritize compound movements that work multiple muscle groups simultaneously:
- Squats and leg press (quadriceps, hamstrings, glutes)
- Deadlifts or Romanian deadlifts (posterior chain, back)
- Rows (back, biceps)
- Chest press (chest, shoulders, triceps)
- Overhead press (shoulders, triceps)
These movements produce the most total muscle stimulus per unit of time.
Progressive overload: Gradually increase weight or resistance over time. The muscle-building signal requires that the work be challenging — not just comfortable movement. If you're not getting harder sessions over weeks, the stimulus plateaus.
Cardio: Moderate cardio (20–30 minutes, 3x/week) is beneficial for cardiovascular health and doesn't substantially interfere with muscle preservation when combined with adequate protein. Excessive cardio (daily long-duration endurance work) can amplify the catabolic environment of caloric restriction.
Sleep and Growth Hormone: Recovery Matters
Deep sleep (slow-wave sleep) is the primary window during which growth hormone (GH) is pulsatilely released. GH is a potent anabolic signal for muscle protein synthesis and a driver of fat oxidation. During caloric restriction (as occurs on GLP-1 therapy), GH secretion dynamics change — and poor sleep dramatically reduces the available GH for muscle recovery.
Practical implications:
- Prioritize 7–9 hours of sleep per night
- Avoid eating heavily before bed (which disrupts GH pulsatility)
- Manage sleep apnea (common in obesity and independently suppresses GH)
- Screen time and blue light reduction improve deep sleep quantity
Creatine Monohydrate: The Most Evidence-Backed Supplement
Among all supplements with claimed muscle-preserving properties, creatine monohydrate has by far the strongest evidence base — particularly in the context of caloric restriction and resistance training.
How it works: Creatine increases phosphocreatine stores in muscle, which regenerates ATP (cellular energy currency) during short-duration, high-intensity exercise. This allows you to do more total work per session, increasing the anabolic training stimulus. Additionally, creatine directly activates satellite cells and promotes muscle fiber growth independent of exercise.
Evidence for lean mass preservation: Multiple meta-analyses show that creatine supplementation during caloric restriction combined with resistance training preserves lean mass significantly better than exercise alone. This is directly applicable to the GLP-1 patient situation.
Standard protocol: 3–5g/day of creatine monohydrate (no loading phase necessary). Inexpensive, safe, and one of the most thoroughly studied performance supplements in existence.
Leucine, BCAAs, and Essential Amino Acids
Beyond total protein, specific amino acid supplementation can help:
Leucine: 2.5–3g of leucine per meal is required to maximally stimulate mTORC1. If meals are small (due to appetite suppression), adding leucine supplement (or a high-leucine protein source like whey) ensures the mTOR trigger is hit.
Essential amino acids (EAAs): A complete essential amino acid supplement (9 EAAs) between meals or around training can stimulate muscle protein synthesis without requiring a full meal — useful when appetite is severely suppressed and eating enough whole food is difficult.
BCAAs alone: Less useful than complete EAAs; they contain only leucine, isoleucine, and valine, missing other essential amino acids needed for complete protein synthesis.
GH Secretagogues and Muscle Preservation (Brief Overview)
Some patients and clinicians explore growth hormone secretagogues as adjunct lean mass preservation strategies during GLP-1 therapy:
- Ipamorelin: A selective GH secretagogue with minimal cortisol or prolactin elevation
- CJC-1295: A GHRH analog that amplifies pulsatile GH release
- MK-677 (Ibutamoren): An oral ghrelin mimetic that stimulates GH secretion
These compounds are not FDA-approved for muscle preservation and remain experimental/research-use only. They carry their own risk profiles (insulin resistance, water retention with MK-677; pituitary down-regulation with prolonged GHRH analog use). These approaches should only be considered under experienced medical supervision and are beyond the scope of standard clinical practice.
Monitoring: How to Know If You're Losing Too Much Muscle
You can't guess your way through body composition management. Use objective measurements:
DEXA scan: Gold standard for distinguishing fat mass from lean mass. A baseline before starting GLP-1 therapy plus repeat scans at 3–6 month intervals allows precise tracking. Look for the fat-to-lean ratio of weight loss — ideally, 70%+ of lost weight should be fat.
Bioimpedance analysis (BIA): Less accurate than DEXA but widely accessible (InBody machines at many gyms and clinics). Good for trend tracking in consistent conditions (same time of day, hydration status). Less reliable on GLP-1 drugs due to fluid changes.
Functional strength tests: Can you lift as much as you could 3 months ago? Are you maintaining or improving performance on compound lifts? Grip strength (measured with a hand dynamometer) is a validated functional proxy for overall muscle mass and is predictive of health outcomes.
Warning signs of excessive lean mass loss: Unexpected rapid strength decline, persistent extreme fatigue not explained by sleep or electrolytes, inability to perform activities of daily living, new falls or balance problems (particularly in older adults).
Evidence-Based Intervention Comparison Table
| Intervention | Expected Benefit | Evidence Strength | Practical Difficulty |
|---|
| Protein intake 1.6g/kg/day | High — reduces lean mass loss by 30–50%+ | Strong (multiple RCTs and meta-analyses) | Moderate (requires meal planning) |
| Resistance training 3–4×/week | Very High — can prevent all lean mass loss | Strong (case series; analogy from other caloric restriction studies) | Moderate-High (time and consistency required) |
| Creatine monohydrate 3–5g/day | Moderate — augments training effects | Strong (extensive meta-analyses) | Low (inexpensive, simple) |
| Adequate sleep (7–9hrs) | Moderate — preserves GH pulsatility | Moderate (mechanistic evidence strong; direct GLP-1 RCT limited) | Variable |
| Leucine optimization per meal | Moderate — ensures mTOR activation | Moderate (mechanistic; strong in protein literature) | Low |
| DEXA monitoring | Diagnostic only — informs strategy | High (clinical utility) | Low (accessible at many clinics) |
| GH secretagogues | Potentially High — but unproven in GLP-1 context | Low-Moderate (exploratory) | High (off-label; medical supervision required) |
Frequently Asked Questions
Q: How much muscle do people typically lose on GLP-1 drugs like semaglutide?
A: Clinical trial DEXA substudy data show that lean soft tissue accounts for approximately 26–40% of total weight lost on GLP-1 drugs. In the STEP 1 semaglutide trial, participants lost approximately 6.9 kg of lean tissue alongside 10.4 kg of fat over 68 weeks. In the SURMOUNT-1 tirzepatide trial, lean tissue accounted for about 26% of total weight lost. These figures are for patients receiving standard lifestyle counseling, not optimized resistance training and protein protocols.
Q: Is muscle loss on GLP-1 drugs inevitable?
A: No — muscle loss is not inevitable. Case series published in 2025 documented patients on semaglutide and tirzepatide who actually gained lean mass while losing substantial total body weight, by following structured resistance training (3–5 days/week) and high protein intake. The degree of muscle loss is heavily modifiable through intentional exercise and nutrition strategies.
Q: How much protein should you eat on GLP-1 drugs to prevent muscle loss?
A: The evidence-based target is approximately 1.6–2.2g of protein per kg of ideal body weight per day. The LEAN-PREP clinical trial uses 1.6g/kg/day as its protein intervention target, based on the meta-regression by Morton et al. that identified this as the threshold for maximizing muscle preservation with resistance training. Older adults and women (higher risk groups) should target the upper end of this range. Protein should be distributed across 4–5 meals with at least 25–40g (and ~2.5–3g leucine) per meal.
Q: What type of exercise is most important for preserving muscle on GLP-1 drugs?
A: Resistance training (strength training with weights, resistance bands, or bodyweight against significant resistance) is the most important exercise modality. It directly stimulates mTORC1-mediated muscle protein synthesis through mechanical loading — an anabolic signal that counteracts the catabolic environment of caloric restriction. Compound movements (squats, deadlifts, rows, presses) are most efficient, targeting multiple muscle groups simultaneously with progressive overload over time.
Q: Can you build muscle while losing weight on semaglutide or tirzepatide?
A: Yes, in some patients. Case studies published in 2025 documented two patients on GLP-1 drugs who increased lean soft tissue by 2.5% and 5.8% respectively while losing 13–27% total body weight, through consistent resistance training and high protein intake. This simultaneous fat loss and muscle gain (body recomposition) is particularly achievable in individuals new to resistance training or who have significant fat reserves to fuel muscle protein synthesis.
Q: Does creatine help preserve muscle on GLP-1 drugs?
A: Yes — creatine monohydrate is one of the best-supported supplements for lean mass preservation during caloric restriction combined with resistance training. Multiple meta-analyses confirm that creatine supplementation significantly improves lean mass outcomes compared to resistance training alone in caloric restriction contexts. The standard dose is 3–5g daily of creatine monohydrate — inexpensive, safe, and well-tolerated by most people.
Q: Why is muscle loss dangerous on GLP-1 drugs?
A: Muscle loss reduces resting metabolic rate (lowering caloric needs and making weight regain more likely when the drug is stopped), accelerates sarcopenia progression (a major risk factor for falls, fractures, and disability in older adults), and paradoxically impairs insulin sensitivity since skeletal muscle is the primary site of insulin-stimulated glucose disposal. Preserving muscle mass is therefore essential not just aesthetically but for the long-term metabolic success of GLP-1 therapy.
Q: Who is most at risk for excessive muscle loss on GLP-1 therapy?
A: Higher risk groups include: older adults (reduced anabolic responsiveness to protein), women (identified in ENDO 2025 data as experiencing greater muscle loss on semaglutide), people with very low protein intake, sedentary individuals not doing resistance training, those experiencing rapid dose escalation, and people with pre-existing sarcopenia or low baseline muscle mass.
Q: How do you monitor muscle loss during GLP-1 therapy?
A: The gold standard is DEXA scanning — a low-radiation imaging technique that measures fat mass and lean mass separately. A baseline scan before starting GLP-1 therapy plus follow-up scans at 3–6 month intervals allows precise tracking of body composition changes. Bioimpedance analysis (InBody machines) is a more accessible alternative. Functional monitoring includes tracking gym performance (are you maintaining or improving strength?), grip strength measurement, and watching for warning signs like rapid strength loss, falls, or inability to perform daily activities.
Q: Does the type of protein matter, or is total protein amount all that matters?
A: Both matter. Total protein quantity is the primary driver, but protein quality also matters — particularly during caloric restriction when every gram counts. Animal proteins (whey, eggs, meat, fish, dairy) have higher digestibility-corrected amino acid scores (DIAAS) and more leucine per gram than most plant proteins, resulting in greater muscle protein synthesis per gram consumed. Vegetarians and vegans should target 20–30% more total protein to compensate for lower bioavailability.
Q: How does sleep affect muscle preservation on GLP-1 drugs?
A: Sleep is a critical anabolic window. The majority of growth hormone (GH) secretion — a potent muscle preservation signal — occurs during slow-wave (deep) sleep. Inadequate sleep or poor sleep quality substantially reduces GH release, undermining muscle recovery and synthesis. Additionally, poor sleep elevates cortisol (catabolic) and reduces insulin sensitivity. Targeting 7–9 hours of quality sleep and addressing sleep apnea (common in obesity) are important complementary strategies alongside protein and resistance training.
Key Takeaways
- 25–40% of weight lost on GLP-1 drugs may be lean tissue (muscle), not fat — based on DEXA data from STEP 1 and SURMOUNT-1 trials. This is the benchmark without optimized exercise and nutrition.
- Muscle loss is not inevitable — patients doing structured resistance training and eating adequate protein have lost minimal lean mass or even gained muscle on GLP-1 drugs.
- The mechanism: GLP-1 drugs suppress appetite dramatically, creating a caloric deficit that — without countermeasures — produces mTOR suppression, negative nitrogen balance, and muscle catabolism.
- Protein target: 1.6–2.2g/kg ideal body weight per day, distributed across 4–5 meals with ≥25–40g per meal. This is non-negotiable during GLP-1 therapy.
- Resistance training (3–5x/week with compound movements and progressive overload) is the single most effective intervention for preserving lean mass.
- Creatine monohydrate (3–5g/day) is the best-supported supplement for lean mass preservation with strong meta-analytic evidence.
- Leucine (2.5–3g per meal) is the key mTOR trigger — ensure each protein meal hits this threshold.
- Monitor with DEXA scans every 3–6 months to ensure the fat-to-lean ratio of weight loss remains favorable (ideally >70% fat loss).
- Older adults and women are at highest risk and require the most proactive approach.
- Sleep matters — 7–9 hours of quality sleep preserves growth hormone pulsatility critical for muscle recovery.
Citations & References
-
Morton RW, et al. "A systematic review, meta-analysis and meta-regression of the effect of protein supplementation on resistance training-induced gains in muscle mass and strength in healthy adults." British Journal of Sports Medicine. 2018. Referenced via: https://ctv.veeva.com/study/lean-mass-preservation-with-resistance-exercise-and-protein-during-semaglutide-tirzepatide-therapy
-
Sheridan RN, et al. "Preservation of lean soft tissue during weight loss induced by GLP-1 receptor agonists." SAGE Open Medical Case Reports. 2025. https://pmc.ncbi.nlm.nih.gov/articles/PMC12536186/
-
Haines M, et al. "Consuming more protein may protect patients taking anti-obesity drug from muscle loss." Endocrine Society ENDO 2025. https://www.endocrine.org/news-and-advocacy/news-room/endo-annual-meeting/endo-2025-press-releases/haines-press-release
-
Fella Health. "Does Semaglutide Cause Muscle Loss? Research and Prevention Strategies." 2025. https://www.fellahealth.com/guide/does-semaglutide-cause-muscle-loss
-
Endocrinology Advisor. "Tirzepatide Significantly Reduces Fat Mass, Preserves Lean Mass in Obesity." 2025. https://www.endocrinologyadvisor.com/news/tirzepatide-significantly-reduces-fat-mass-preserves-lean-mass/
-
American Diabetes Association. "New GLP-1 Therapies Enhance Quality of Weight Loss by Improving Muscle." 2025. https://diabetes.org/newsroom/press-releases/new-glp-1-therapies-enhance-quality-weight-loss-improving-muscle-0
-
LEAN-PREP Trial. ClinicalTrials.gov NCT06885736. https://ctv.veeva.com/study/lean-mass-preservation-with-resistance-exercise-and-protein-during-semaglutide-tirzepatide-therapy
-
Wilding JPH, et al. STEP 1 Trial. New England Journal of Medicine. 2021. https://www.nejm.org/doi/full/10.1056/NEJMoa2032183
-
Jastreboff AM, et al. SURMOUNT-1 Trial. New England Journal of Medicine. 2022. https://www.nejm.org/doi/full/10.1056/NEJMoa2206038
-
CardioMender. "Tirzepatide Bodybuilding: Can You Burn Fat Without Losing Muscle?" 2025. https://www.cardiomenderweightloss.com/tirzepatide-bodybuilding/
